FDA Finds Beckman Coulter Troponin Test Modified Without Proper Clearance

Beckman Coulter will likely need to restrict use of its AccuTn1 troponin test kit in response to FDA findings that the firm modified the assay without proper clearance, the company said March 22

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight